Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems, today announced that Bob Azelby, Eliem’s president and chief executive officer, will present at the 5th Annual Evercore ISI HealthCONx Virtual Conference being held virtually on Thursday, December 1, 2022 at 11:40 AM ET.
A live webcast will be available on the Investors section of the Eliem Therapeutics website at https://www.eliemtx.com. An archived replay will remain available on Eliem’s website for at least 30 days after the conference.
About Eliem Therapeutics, Inc.
Elem Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders. Eliem channels its experience, energy, and passion for improving patients’ quality of life to fuel our efforts to develop life-changing novel therapies. At its core, the Eliem team is motivated by the promise of helping patients live happier, more fulfilling lives.
Session Details TBA
Conference Boxed Lunches - For Diamond, Platinum, Super Pass, Exhibitor/Conference, Speaker, Press Pass Holders